Compare Evergy Inc. Common Stock (EVRG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Evergy Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Evergy Inc. Common Stock trades at $82.56 (market cap $18.94B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3× Evergy Inc. Common Stock's market cap, and Evergy Inc. Common Stock pays a 3.38% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| EVRG | NTRA | |
|---|---|---|
Market Cap | $18.94B | $57.03B |
Volume | 1,640,293 | 1,131,157 |
Sector | Utilities | Health |
52-Week High | $88.13 | $425.64 |
52-Week Low | $72.31 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $35.41B | $56.18B |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Evergy (EVRG) trades at $82.13, up 0.77% today, with a bullish technical signal and strong support near $80. The stock shows solid fundamentals with a P/E of 20.9 and net income margin of 15.19%, supported by recent earnings beats in Q1 and Q2 2026. Positive sentiment is driven by data center demand growth and a $21.6 billion investment plan, as highlighted in recent news.
The outlook for EVRG is positive, with analyst consensus pointing to a $89.83 price target and 38.89% buy ratings. Key opportunities include load growth from data center contracts and projected 6-8% EPS growth through 2030. Risks involve regulatory challenges, high capital expenditures, and potential volatility from interest rate sensitivity.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Evergy Inc. Common Stock
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
